Overcoming rituximab drug-resistance by the genetically engineered anti-CD20-hIFN-α fusion protein: Direct cytotoxicity and synergy with chemotherapy

Treatment of patients with B-NHL with rituximab and CHOP has resulted in significant clinical responses. However, a subset of patients develops resistance to further treatments. The mechanism of unresponsiveness in vivo is not known. We have reported the development of rituximab-resistant clones der...

Descripción completa

Detalles Bibliográficos
Autores principales: VEGA, GABRIEL G., FRANCO-CEA, LUZ ARELI, HUERTA-YEPEZ, SARA, MAYANI, HÉCTOR, MORRISON, SHERIE L., BONAVIDA, BENJAMIN, VEGA, MARIO I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2015
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4735703/
https://www.ncbi.nlm.nih.gov/pubmed/26398317
http://dx.doi.org/10.3892/ijo.2015.3170

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4735703/
https://www.ncbi.nlm.nih.gov/pubmed/26398317
http://dx.doi.org/10.3892/ijo.2015.3170

Ejemplares similares